| Cash Flow | 2025-06-30 |
|---|---|
| Equity based compensation | 1,470,491 |
| Net loss | -19,310,155 |
| Non-cash lease expense | 2,970 |
| Share-based payments for services | 587,285 |
| Prepaid expenses | 13,874 |
| Due to employees | 806,214 |
| Increase (decrease) in deposits | -4,000 |
| Accrued expenses | -60,490 |
| Accounts payable | 2,444 |
| Depreciation and amortization | 2,924,303 |
| Shares issued for settlement of clinical development costs | 350,885 |
| Supplies used for r&d and manufacturing | -622,831 |
| Loss on patent impairment | 13,312 |
| Common stock contributed to 401 plan | 164,510 |
| Net cash used in operating activities | -12,449,214 |
| Purchases of property and equipment | 32,954 |
| Expenditures for patent costs | 0 |
| Net cash used in investing activities | -32,954 |
| Payments of notes payable | 350,000 |
| Payments on obligations under finance leases | 1,491,617 |
| Proceeds from notes payable | 350,000 |
| Proceeds from the purchase of stock by officers and directors | 0 |
| Proceeds from issuance of common stock and pre-funded warrants | 12,560,300 |
| Payments of stock issuance costs | 1,531,832 |
| Net cash provided by financing activities | 9,536,851 |
| Net decrease in cash and cash equivalents | -2,945,317 |
CEL SCI CORP (CVM)
CEL SCI CORP (CVM)